Avadel Pharmaceuticals Q3 2024 GAAP EPS $(0.03) Beats $(0.06) Estimate, Sales $50.025M Beat $48.607M Estimate
Avadel Pharmaceuticals Q3 2024 GAAP EPS $(0.03) Beats $(0.06) Estimate, Sales $50.025M Beat $48.607M Estimate
avadel pharmaceuticals 2024年第三季度 GAAP 每股收益 $(0.03)，超出 $(0.06) 估计，销售额 $5002.5万，超出 $4860.7万 估计
Avadel Pharmaceuticals (NASDAQ:AVDL) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.06) by 50 percent. This is a 92.68 percent increase over losses of $(0.41) per share from the same period last year. The company reported quarterly sales of $50.025 million which beat the analyst consensus estimate of $48.607 million by 2.92 percent. This is a 613.22 percent increase over sales of $7.014 million the same period last year.
Avadel Pharmicals（纳斯达克股票代码：AVDL）公布的季度亏损为每股0.03美元，比分析师普遍预期的0.06美元（0.06美元）高出50％。与去年同期每股亏损0.41美元（0.41美元）相比，增长了92.68％。该公司公布的季度销售额为5,025万美元，比分析师普遍预期的4,860.7万美元高出2.92％。这比去年同期701.4万美元的销售额增长了613.22％。
热门讨论
FOMC维持利率但不确定性高企：美股后市走向如何？
🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？
Moo Live
03/20 02:25
联邦公开市场委员会新闻发布会，2025年3月19日